

<b>Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/995,731	SANKARANARAYANAN, ALANGUDI	
	<b>Examiner</b>	<b>Art Unit</b>	
	Binta M. Robinson	1625	

All participants (applicant, applicant's representative, PTO personnel):

(1) Binta M. Robinson. 

(2) Allan Rotman. 

(3) Feng Lu.

(4) Susan Mack. 

Date of Interview: 06 June 2003.

Type: a) Telephonic b) Video Conference  
 c) Personal [copy given to: 1) applicant      2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.  
 If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: 1-14, 16-29, 31-34, 36-39, 41-44, 46-63, 65-69, 71-75 and 77-90.

Identification of prior art discussed: \_\_\_\_\_.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

\_\_\_\_\_  
 Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The applicant's representatives and examiner agreed that claims 3, 6, 9, 12-14, 27-29, 32-34, 37-39, 42-44, 52, 55-56, 58, 61-63, 67-69, and 73-75 also read on the elected species as do claims 1, 2, 4, 5, 7, 8, 10, 11, 16-26, 31, 36, 41, 46-50, 53, 54, 57, 59, 60, 65, 66, 71, 72, 77-90 and will be examined in the next office action. The examiner and applicant's representative agreed that the elected restricted group I at paper no. 11 will be revised where X is everything claimed, R2 is everything claimed except heteroaryl, R7 is everything claimed except heteroaryl, R1 is N(R7)R9, where R9 is as defined at paper no. 9, R3 is thienyl,. Applicants' representative agreed to address claim 17 which is an improper product use claim. Applicants' representative also will ask the applicant to consider overcoming the 112, first paragraph rejection of the term "prevention" or "preventing" by substituting the term "treating" or "delaying the onset" or "prolonging the onset". Applicant's representative will also ask the applicant to consider overcoming the 112, first paragraph enablement rejection of the term "heteroaryl" wherever it appears in the compound, as well as the phrase "diseases caused by accumulation of free radicals in the body cells" in claim 71. Applicant's representative will also ask the applicant to consider overcoming the 112, first paragraph enablement rejection of parts a and e of claim 82, phrases which are too generic..